Cargando…
HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor
BACKGROUND: To develop peptide-based immunotherapy for osteosarcoma, we previously identified papillomavirus binding factor (PBF) as a CTL-defined osteosarcoma antigen in the context of HLA-B55. However, clinical application of PBF-based immunotherapy requires identification of naturally presented C...
Autores principales: | Tsukahara, Tomohide, Kawaguchi, Satoshi, Torigoe, Toshihiko, Takahashi, Akari, Murase, Masaki, Kano, Masanobu, Wada, Takuro, Kaya, Mitsunori, Nagoya, Satoshi, Yamashita, Toshihiko, Sato, Noriyuki |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702281/ https://www.ncbi.nlm.nih.gov/pubmed/19523231 http://dx.doi.org/10.1186/1479-5876-7-44 |
Ejemplares similares
-
High Expression of CD109 Antigen Regulates the Phenotype of Cancer Stem-Like Cells/Cancer-Initiating Cells in the Novel Epithelioid Sarcoma Cell Line ESX and Is Related to Poor Prognosis of Soft Tissue Sarcoma
por: Emori, Makoto, et al.
Publicado: (2013) -
A quest for therapeutic antigens in bone and soft tissue sarcoma
por: Kawaguchi, Satoshi, et al.
Publicado: (2005) -
Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients
por: Cui, Tingting, et al.
Publicado: (2016) -
Identification of Two Novel HLA-A*0201-Restricted CTL Epitopes Derived from MAGE-A4
por: Jia, Zheng-Cai, et al.
Publicado: (2010) -
TNP-470 Suppresses the Tumorigenicity of HT1080 Fibrosarcoma Tumor
Through the Inhibition of VEGF Secretion From the Tumor Cells
por: Kaya, Mitsunori, et al.
Publicado: (2001)